SAN RAFAEL, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that the Company will participate at the Centers for Medicare & Medicaid Services’ (“CMS”) Healthcare Common Procedure Coding System (“HCPCS”) public meeting on November 29, 2023, to discuss appropriate Medicare payment... Read More

Ruling Could Significantly Expand Use of Ekso Indego Personal in Home and Community Markets SAN RAFAEL, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, announces that the Centers for Medicare & Medicaid Services (“CMS”) finalized its Calendar Year 2024 Home Health Prospective Payment System Rule... Read More

SAN RAFAEL, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and nine months ended September 30, 2023. Recent Highlights and Accomplishments Reported revenue of $4.6 million in the third quarter of 2023, an increase of 38% year-over-year Sold a total... Read More

SAN RAFAEL, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2023 after the close of trading on Thursday, October 26, 2023. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to... Read More

SAN RAFAEL, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, supports the Centers for Medicare & Medicaid Services (“CMS”) proposal to include personal exoskeletons in the Medicare benefit category for braces in the updated 2024 Home Health Prospective Payment System Rate. “This newly proposed... Read More

SAN RAFAEL, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc . (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Scott Davis, Chief Executive Officer, and Jerome Wong, Chief Financial Officer, will be participating in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference taking place in New York on... Read More

SAN RAFAEL, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2023. Recent Highlights and Accomplishments Achieved record revenues of $4.7 million in the second quarter of 2023, an increase of 36% year-over-year Booked a... Read More

SAN RAFAEL, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2023 after the close of trading on Thursday, July 27, 2023. Management will host a conference call beginning at 1:30 p.m. PT /... Read More

Highest Quarterly Revenues in Company History SAN RAFAEL, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2023. Recent Highlights and Accomplishments Achieved record revenues of $4.1 million in the first... Read More

SAN RAFAEL, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2023 after the close of trading on Thursday, April 27, 2023. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to... Read More

SoldierStrong to Donate Device to the Charlie Norwood Department of Veteran Affairs Medical Center in Augusta, GA SAN RAFAEL, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that SoldierStrong, a non-profit organization dedicated to improving Veterans’ lives through innovative technology, has... Read More

SAN RAFAEL, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2022. Recent Highlights and Accomplishments Completed the acquisition of the Human Motion Control (“HMC”) business unit including the Indego ® product... Read More

SAN RAFAEL, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2022 after the close of trading on Tuesday, March 28, 2023. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to... Read More

SAN RAFAEL, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced it will showcase the new Ekso Indego Therapy with Functional Electrical Stimulation (FES) at the upcoming American Physical Therapy Association’s Combined Sections Meeting on February 23-25 in San Diego, California. The Company recently... Read More

Broadens Ekso Bionics’ product portfolio into home use Adds Vanderbilt University as a key commercial and research partner Acquisition consolidates leading lower extremity robotic companies Ekso President and COO Scott Davis promoted to Chief Executive Officer; Steven Sherman to remain Chairman, appointed Executive Chair SAN RAFAEL, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics (Nasdaq: EKSO) (the “Company”), an... Read More

Quarterly Record of 33 EksoNR Bookings in Q3 2022 Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended September 30, 2022. Recent Highlights and Accomplishments Record of 33 EksoNR bookings in the third quarter of 2022 Reported revenue of $3.3 million in the third quarter of 2022, an... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2022 after the close of trading on Thursday, November 3, 2022. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Scott Davis, President and Chief Operating Officer, will be presenting virtually at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022. The pre-recorded presentation will be available to view on-demand as of 4:00 AM PT / 7:00... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended June 30, 2022. Recent Highlights and Accomplishments Reported revenue of $3.5 million in the second quarter of 2022, an increase of 57% year-over-year Received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to... Read More

Ekso Bionics Holdings, Inc . (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2022 after the close of trading on Thursday, July 28, 2022. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business... Read More

First FDA Cleared Exoskeleton for Rehabilitation Use in Patients with Multiple Sclerosis Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its EksoNR™ robotic exoskeleton for use with Multiple Sclerosis (MS) patients. EksoNR is the... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Jerome Wong as Interim Chief Financial Officer following the departure of current CFO Jack Glenn. Mr. Glenn resigned effective June 17, 2022 to pursue a new position at another public company. Mr. Glenn’s resignation is not the result of any dispute or... Read More

Ekso Bionics Holdings, Inc . (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that management will present at the H.C. Wainwright Global Investment Conference taking place May 23-26, 2022. The pre-recorded presentation will be available to view on-demand as of 4:00 AM PT / 7:00 AM ET, Tuesday, May 24, 2022 throughout the entirety of the conference and on the... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2022. Recent Highlights and Accomplishments Reported revenue of $2.6 million in the first quarter of 2022 Strong cash position of $36.2 million at March 31, 2022 Booked a total of 23 EksoNR units in the first quarter of... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2022 after the close of trading on Thursday, April 28, 2022. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2021. Recent Highlights and Accomplishments Reported record revenue of $4.1 million in the fourth quarter of 2021 Achieved gross margin of approximately 59% in the fourth quarter of 2021 Booked a total of 30... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2021 after the close of trading on Thursday, February 24, 2022. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and... Read More

Board Member Steven Sherman to be Appointed CEO EVP Scott Davis to be Appointed President and COO CEO Jack Peurach to Leave the Company Effective January 21, 2022 Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Jack Peurach, who has served as the Company’s Chief Executive Officer since 2018, has informed the... Read More

Company Achieves Record Quarterly Revenue of $3.9 million to $4.1 million 1 Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the fourth quarter and fiscal year ended December 31, 2021. Total revenue for the fourth quarter of 2021 is an estimated range of $3.9 million to $4.1... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022. The fireside chat will be available to view on-demand as of 4:00 AM PT / 7:00 AM ET, Monday, January 10, 2022 throughout the entirety of the conference... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Corinna E. Lathan, Ph.D. to its Board of Directors, effective immediately. “We are pleased to expand our Board with the addition of Dr. Lathan, who brings a successful track record of robotics, engineering and business experience,” said Jack Peurach,... Read More

Foundation Donates Units to Two Inpatient Rehabilitation Facilities in Nebraska Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that the Nebraska Chapter of the Fraternal Order of Eagles (“F.O.E.”), an international nonprofit community organization, has purchased two EksoNR devices on behalf of local Nebraska inpatient... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended September 30, 2021. Recent Highlights and Accomplishments Reported revenue of $3.0 million in the third quarter of 2021 Achieved gross margin of approximately 59% in the third quarter of 2021 Booked a total of 16 EksoNR units in... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2021 after the close of trading on Tuesday, November 2, 2021. Management will host a conference call beginning at 1:30 p.m. PT, 4:30 p.m. ET to discuss the financial results and recent business... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that management will participate in a fireside chat at the H.C. Wainwright 23 rd Annual Global Investor Conference held on September 13 - 15, 2021. The fireside chat will be available to view on-demand as of 4:00 AM PT / 7:00 AM ET, Monday, September 13, 2021 throughout the entirety of the... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended June 30, 2021. Recent Highlights and Accomplishments Reported revenue of $2.2 million in the second quarter of 2021 Achieved gross margin of approximately 58% in the second quarter of 2021 Booked a total of 20 EksoNR units in the... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2021 after the close of trading on Thursday, July 29, 2021. Management will host a conference call beginning at 1:30 p.m. PT, 4:30 p.m. ET to discuss the financial results and recent business developments. A live... Read More

Following Successful Pilot Program, EksoNR will be Available at Four of Kindred’s Long-Term Acute Care Hospitals in Florida Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced an expanded partnership with Kindred Healthcare, LLC ("Kindred") bringing EksoNR, the most clinically used robotic exoskeleton, to four of Kindred’s... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2021. Recent Highlights and Accomplishments Reported revenue of $1.9 million in the first quarter of 2021, an increase of 30% compared to the same period in 2020 Achieved record gross margins of approximately 65% in the... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2021 after the close of trading on Thursday, April 29, 2021. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. A live... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced a partnership with U.S. Physiatry (USP) to educate physicians on the clinical benefits of an EksoNR exoskeleton. USP is the largest inpatient physician practice in the U.S. focused exclusively on physical medicine and rehabilitation. The partnership will help expand... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Performance Contracting, Inc. (“PCI”), a leading U.S. specialty contractor, is the latest company in the construction vertical to implement field testing of EVO™ exoskeleton vests. Over the course of a year, PCI employees in six Bay Area counties have committed to... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that Jack Glenn, Chief Financial Officer, will present at the H.C. Wainwright Global Life Sciences Conference held on March 9 – 10, 2021. A company presentation will be available to view on-demand as of 4:00 AM PT / 7:00 AM ET, Tuesday, March 9, 2021 throughout the entirety of the... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2020. Recent Highlights and Accomplishments Reported revenue of $2.3 million in the fourth quarter of 2020, compared to $3.7 million in the same period of 2019 Achieved gross margins of approximately 60% in... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2020 after the close of trading on Thursday, February 25, 2021. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced the closing of its previously announced underwritten public offering of 3,902,440 shares of common stock of Ekso Bionics, at a price to the public of $10.25 per share, less underwriting discounts and commissions. As previously announced, Ekso Bionics also has granted to the... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 3,902,440 shares of common stock of Ekso Bionics, at a price to the public of $10.25 per share, less underwriting... Read More

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 975,610 shares of common stock of Ekso Bionics, at a price to the public of $10.25 per share, less underwriting... Read More